By Ross Kerber and Christian Martinez Dec 11 (Reuters) - U.S. President Donald Trump signed an executive order aimed at increasing oversight of the proxy advisory industry, the White House said on Thursday, saying top firms often "advance and prioritize radical politically-motivated agendas." In the order, posted on the White House website, ​Trump directed the U.S. Securities and Exchange Commission and other agencies to review if top proxy advisers Institutional Shareholder Services and Glass Lewis had ...

Egan-Jones Cites Cannae's "Financial Underperformance", "Misaligned Capital Allocation", "Lack of Credible Shareholder Distribution Plan" and "Governance Concerns" in Joining ISS and Glass Lewis in Recommending Cannae Shareholders Elect ALL FOUR of Carronade's NomineesAll Three Advisory Firms Unanimously Support Carronade's Compelling Case for Change and Endorse Nominees Mona Aboelnaga, Benjamin Duster, Dennis Prieto and Chérie SchaibleRecommends Shareholders "WITHHOLD" on All Four Cannae NomineesDARIEN, Co ...

Your vote is important no matter how many Shares or Options of Tornado you hold. The Board of Directors of Tornado recommends that Securityholders vote FOR the Arrangement Resolution. ...

Core Viewpoint - All three leading proxy advisory firms, ISS, Glass Lewis, and Egan-Jones, have recommended that stockholders vote "FOR" Wendy L. Dixon, Ph.D. and Tamara A. Favorito, while advising to "WITHHOLD" votes for dissident nominees Travis Mickle and Arthur Regan, indicating a lack of compelling case for change from the dissident [1][2][4]. Proxy Advisory Recommendations - The Zevra Board of Directors expressed satisfaction with the unanimous endorsement from the proxy advisors, reinforcing their commitment to stockholder value creation under current leadership [2]. - Proxy advisors concluded that the dissident, Mangless, failed to provide sufficient arguments for electing his nominees, lacking a clear strategy to enhance stockholder value [2][5]. Shareholder Returns - Proxy advisors highlighted significant total shareholder returns under Zevra's current management, with ISS noting that the company has outperformed the broader biotech market during McFarlane's tenure as CEO [3][5]. - Egan-Jones emphasized that the past two years have yielded exceptional returns, surpassing both the total market and the S&P Biotech ETF [5]. Concerns About Dissident Nominees - ISS raised concerns about the potential disruption that electing the dissident nominees could cause, particularly highlighting the risks associated with having a former CEO on the board [5]. - Glass Lewis pointed out that Mangless did not present a meaningful alternative strategy for Zevra, lacking a clear plan to improve operational efficacy [5][13]. - Egan-Jones questioned the relevant expertise of Mangless' nominees, suggesting that their backgrounds do not offer meaningful value to Zevra's board [13].